

Biography

Sharon M. Erdman, Pharm.D., is currently a Clinical Professor in the Department of Pharmacy Practice at the Purdue University College of Pharmacy, and an Infectious Diseases Clinical Pharmacist and Co-Director of the Outpatient Parenteral Antimicrobial Therapy Program (OPAT) at Eskenazi Health in Indianapolis, Indiana. Dr. Erdman received her Pharm.D. degree from the University of Illinois at Chicago College of Pharmacy in 1990, where she subsequently completed a specialized residency (1990-1991) and fellowship (1991-1992) in the areas of Infectious Diseases and Pharmacokinetics under the guidance of Dr. Keith Rodvold.

Sharon has worked as an Infectious Diseases Clinical Pharmacist from 1992-1999 (Loyola University Medical Center, Maywood, Illinois) and 2004-present (Eskenazi Health). She has developed and co-directed OPAT programs at both medical centers. Throughout her career, she has been actively involved in the professional education of pharmacy students, pharmacy residents, medical students, medical residents, infectious diseases fellows, nursing students and physician assistant students addressing infectious diseases pharmacotherapy and HIV pharmacotherapy. Dr. Erdman is also involved as a principal investigator or co-investigator in numerous research projects in the areas of infectious diseases pharmacotherapy and pharmacokinetics, with current projects including 1) economic and clinical outcomes of averted OPAT; 2) correlation of adherence to the 2012 Infectious Diseases Society of America practice guidelines with patient outcomes in the treatment of diabetic foot infections in an OPAT program; 3) outcomes of orthopedic hardware-related osteomyelitis treated via a county hospital OPAT program; 4) adverse events and line complications during OPAT at an inner-city, county teaching hospital; and 5) pharmacokinetics of vancomycin in obese patients.

Dr. Erdman has previously served SIDP as chair of the Program Committee (2004-2006), Chair of the Membership Committee (2006-2008), member of the Inter-Organizational Committee (2009-2010), Secretary/Treasurer (2010-2012), and member of the Program Committee (2013-2014). She is currently a member of the Clinical and Laboratory Standards Institute (CLSI) Working Group for Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data (antibiogram development {M39}), a member of the Indiana Coalition for Antimicrobial Resistance Education (ICARE), and a member of the Indiana State Department of Health Tuberculosis Medical Advisory Board and HIV Medical Ad Hoc Committee.

Campaign Statement

I am truly honored to be nominated for the position of President-Elect of the Society of Infectious Diseases Pharmacists. Throughout my career, I have been a dedicated member of SIDP and have been an active participant in the Society. This nomination offers a wonderful opportunity to further contribute to the current initiatives of SIDP and identify new areas for growth for the Society in a leadership position. If elected as President, I would continue to advance the mission of the Society with regard to: 1) enhancing the role of pharmacists within the infectious diseases community, including both medical and regulatory communities; 2) developing and maintaining standards of practice for infectious diseases pharmacists; 3) supporting and promoting research addressing the prevention or treatment of infectious diseases; and 4) providing educational programs surrounding the appropriate use of antimicrobial agents to pharmacists and other healthcare professionals. In addition, as President, I would strive to identify the evolving needs and issues of the Society (including the needs and issues of individual members) and would work to identify new opportunities to enhance the growth and professional stature of the Society. During the past few years, great strides have been made in advancing the role of infectious diseases pharmacists in governmental initiatives/healthcare policy and within the medical community. As President-Elect, I would continue to support these initiatives by nurturing collaborative relationships with important infectious diseases colleagues, such as IDSA, ASM, CLSI and others, while continuing to illustrate the importance of pharmacy involvement at all critical stages of policy and guideline development. I would continue to work on developing standards of practice for infectious diseases pharmacists and explore the opportunity of SIDP to provide board certification of this specialty, if possible. I would continue to pursue opportunities for support of infectious diseases-related post-doctoral training and research to foster continued subspecialty in this area. And lastly, since SIDP has taken a leadership role in providing antimicrobial stewardship training to pharmacists through its Antimicrobial Stewardship Certificate Program, I would continue to look for opportunities to provide this training to other healthcare professionals as well as pursue opportunities to develop additional educational programs on the appropriate use of antimicrobial agents. It would certainly be an honor for me to contribute to the development and further advancement of SIDP!